Postmenopausal Vaginal Atrophy Therapeutics Market, Global Outlook and Forecast 2022-2028

April 2022 | 60 pages | ID: PDFF4DA45B76EN
Market Monitor Global

Abstracts

Postmenopausal vaginal atrophy (PVA), also referred to as postmenopausal atrophic vaginitis, caused by the vaginal walls' drying, thinning, and inflammation due to reduced estrogen levels. Women with this disorder are more vulnerable to problems of urinary system and chronic infection of vaginal linings. A variety of medications and therapies available in market that focuses on the underlying cause as well as the symptoms of the condition. These therapies also helps women to improve their quality of life.

This report contains market size and forecasts of Postmenopausal Vaginal Atrophy Therapeutics in Global, including the following market information:

Global Postmenopausal Vaginal Atrophy Therapeutics Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Postmenopausal Vaginal Atrophy Therapeutics market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Estrogen-based Drugs Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Postmenopausal Vaginal Atrophy Therapeutics include Endoceutics, Accord Healthcare, Pfizer, Novo Nordisk, Teva Pharmaceuticals, Shionogi, Bionovo, QuatRx Pharmaceutical Company and Bayer AG and etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Postmenopausal Vaginal Atrophy Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Postmenopausal Vaginal Atrophy Therapeutics Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Postmenopausal Vaginal Atrophy Therapeutics Market Segment Percentages, by Type, 2021 (%)

• Estrogen-based Drugs
• Non-estrogen-based Drugs

Global Postmenopausal Vaginal Atrophy Therapeutics Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Postmenopausal Vaginal Atrophy Therapeutics Market Segment Percentages, by Application, 2021 (%)

• Hospital
• Specialist Clinic

Global Postmenopausal Vaginal Atrophy Therapeutics Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Postmenopausal Vaginal Atrophy Therapeutics Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Postmenopausal Vaginal Atrophy Therapeutics revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Postmenopausal Vaginal Atrophy Therapeutics revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Endoceutics
• Accord Healthcare
• Pfizer
• Novo Nordisk
• Teva Pharmaceuticals
• Shionogi
• Bionovo
• QuatRx Pharmaceutical Company
• Bayer AG
• TherapeuticsMD

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Postmenopausal Vaginal Atrophy Therapeutics Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Postmenopausal Vaginal Atrophy Therapeutics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL POSTMENOPAUSAL VAGINAL ATROPHY THERAPEUTICS OVERALL MARKET SIZE

2.1 Global Postmenopausal Vaginal Atrophy Therapeutics Market Size: 2021 VS 2028
2.2 Global Postmenopausal Vaginal Atrophy Therapeutics Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Postmenopausal Vaginal Atrophy Therapeutics Players in Global Market
3.2 Top Global Postmenopausal Vaginal Atrophy Therapeutics Companies Ranked by Revenue
3.3 Global Postmenopausal Vaginal Atrophy Therapeutics Revenue by Companies
3.4 Top 3 and Top 5 Postmenopausal Vaginal Atrophy Therapeutics Companies in Global Market, by Revenue in 2021
3.5 Global Companies Postmenopausal Vaginal Atrophy Therapeutics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Postmenopausal Vaginal Atrophy Therapeutics Players in Global Market
  3.6.1 List of Global Tier 1 Postmenopausal Vaginal Atrophy Therapeutics Companies
  3.6.2 List of Global Tier 2 and Tier 3 Postmenopausal Vaginal Atrophy Therapeutics Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Postmenopausal Vaginal Atrophy Therapeutics Market Size Markets, 2021 & 2028
  4.1.2 Estrogen-based Drugs
  4.1.3 Non-estrogen-based Drugs
4.2 By Type - Global Postmenopausal Vaginal Atrophy Therapeutics Revenue & Forecasts
  4.2.1 By Type - Global Postmenopausal Vaginal Atrophy Therapeutics Revenue, 2017-2022
  4.2.2 By Type - Global Postmenopausal Vaginal Atrophy Therapeutics Revenue, 2023-2028
  4.2.3 By Type - Global Postmenopausal Vaginal Atrophy Therapeutics Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Postmenopausal Vaginal Atrophy Therapeutics Market Size, 2021 & 2028
  5.1.2 Hospital
  5.1.3 Specialist Clinic
5.2 By Application - Global Postmenopausal Vaginal Atrophy Therapeutics Revenue & Forecasts
  5.2.1 By Application - Global Postmenopausal Vaginal Atrophy Therapeutics Revenue, 2017-2022
  5.2.2 By Application - Global Postmenopausal Vaginal Atrophy Therapeutics Revenue, 2023-2028
  5.2.3 By Application - Global Postmenopausal Vaginal Atrophy Therapeutics Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Postmenopausal Vaginal Atrophy Therapeutics Market Size, 2021 & 2028
6.2 By Region - Global Postmenopausal Vaginal Atrophy Therapeutics Revenue & Forecasts
  6.2.1 By Region - Global Postmenopausal Vaginal Atrophy Therapeutics Revenue, 2017-2022
  6.2.2 By Region - Global Postmenopausal Vaginal Atrophy Therapeutics Revenue, 2023-2028
  6.2.3 By Region - Global Postmenopausal Vaginal Atrophy Therapeutics Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Postmenopausal Vaginal Atrophy Therapeutics Revenue, 2017-2028
  6.3.2 US Postmenopausal Vaginal Atrophy Therapeutics Market Size, 2017-2028
  6.3.3 Canada Postmenopausal Vaginal Atrophy Therapeutics Market Size, 2017-2028
  6.3.4 Mexico Postmenopausal Vaginal Atrophy Therapeutics Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Postmenopausal Vaginal Atrophy Therapeutics Revenue, 2017-2028
  6.4.2 Germany Postmenopausal Vaginal Atrophy Therapeutics Market Size, 2017-2028
  6.4.3 France Postmenopausal Vaginal Atrophy Therapeutics Market Size, 2017-2028
  6.4.4 U.K. Postmenopausal Vaginal Atrophy Therapeutics Market Size, 2017-2028
  6.4.5 Italy Postmenopausal Vaginal Atrophy Therapeutics Market Size, 2017-2028
  6.4.6 Russia Postmenopausal Vaginal Atrophy Therapeutics Market Size, 2017-2028
  6.4.7 Nordic Countries Postmenopausal Vaginal Atrophy Therapeutics Market Size, 2017-2028
  6.4.8 Benelux Postmenopausal Vaginal Atrophy Therapeutics Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Postmenopausal Vaginal Atrophy Therapeutics Revenue, 2017-2028
  6.5.2 China Postmenopausal Vaginal Atrophy Therapeutics Market Size, 2017-2028
  6.5.3 Japan Postmenopausal Vaginal Atrophy Therapeutics Market Size, 2017-2028
  6.5.4 South Korea Postmenopausal Vaginal Atrophy Therapeutics Market Size, 2017-2028
  6.5.5 Southeast Asia Postmenopausal Vaginal Atrophy Therapeutics Market Size, 2017-2028
  6.5.6 India Postmenopausal Vaginal Atrophy Therapeutics Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Postmenopausal Vaginal Atrophy Therapeutics Revenue, 2017-2028
  6.6.2 Brazil Postmenopausal Vaginal Atrophy Therapeutics Market Size, 2017-2028
  6.6.3 Argentina Postmenopausal Vaginal Atrophy Therapeutics Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Postmenopausal Vaginal Atrophy Therapeutics Revenue, 2017-2028
  6.7.2 Turkey Postmenopausal Vaginal Atrophy Therapeutics Market Size, 2017-2028
  6.7.3 Israel Postmenopausal Vaginal Atrophy Therapeutics Market Size, 2017-2028
  6.7.4 Saudi Arabia Postmenopausal Vaginal Atrophy Therapeutics Market Size, 2017-2028
  6.7.5 UAE Postmenopausal Vaginal Atrophy Therapeutics Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Endoceutics
  7.1.1 Endoceutics Corporate Summary
  7.1.2 Endoceutics Business Overview
  7.1.3 Endoceutics Postmenopausal Vaginal Atrophy Therapeutics Major Product Offerings
  7.1.4 Endoceutics Postmenopausal Vaginal Atrophy Therapeutics Revenue in Global Market (2017-2022)
  7.1.5 Endoceutics Key News
7.2 Accord Healthcare
  7.2.1 Accord Healthcare Corporate Summary
  7.2.2 Accord Healthcare Business Overview
  7.2.3 Accord Healthcare Postmenopausal Vaginal Atrophy Therapeutics Major Product Offerings
  7.2.4 Accord Healthcare Postmenopausal Vaginal Atrophy Therapeutics Revenue in Global Market (2017-2022)
  7.2.5 Accord Healthcare Key News
7.3 Pfizer
  7.3.1 Pfizer Corporate Summary
  7.3.2 Pfizer Business Overview
  7.3.3 Pfizer Postmenopausal Vaginal Atrophy Therapeutics Major Product Offerings
  7.3.4 Pfizer Postmenopausal Vaginal Atrophy Therapeutics Revenue in Global Market (2017-2022)
  7.3.5 Pfizer Key News
7.4 Novo Nordisk
  7.4.1 Novo Nordisk Corporate Summary
  7.4.2 Novo Nordisk Business Overview
  7.4.3 Novo Nordisk Postmenopausal Vaginal Atrophy Therapeutics Major Product Offerings
  7.4.4 Novo Nordisk Postmenopausal Vaginal Atrophy Therapeutics Revenue in Global Market (2017-2022)
  7.4.5 Novo Nordisk Key News
7.5 Teva Pharmaceuticals
  7.5.1 Teva Pharmaceuticals Corporate Summary
  7.5.2 Teva Pharmaceuticals Business Overview
  7.5.3 Teva Pharmaceuticals Postmenopausal Vaginal Atrophy Therapeutics Major Product Offerings
  7.5.4 Teva Pharmaceuticals Postmenopausal Vaginal Atrophy Therapeutics Revenue in Global Market (2017-2022)
  7.5.5 Teva Pharmaceuticals Key News
7.6 Shionogi
  7.6.1 Shionogi Corporate Summary
  7.6.2 Shionogi Business Overview
  7.6.3 Shionogi Postmenopausal Vaginal Atrophy Therapeutics Major Product Offerings
  7.6.4 Shionogi Postmenopausal Vaginal Atrophy Therapeutics Revenue in Global Market (2017-2022)
  7.6.5 Shionogi Key News
7.7 Bionovo
  7.7.1 Bionovo Corporate Summary
  7.7.2 Bionovo Business Overview
  7.7.3 Bionovo Postmenopausal Vaginal Atrophy Therapeutics Major Product Offerings
  7.7.4 Bionovo Postmenopausal Vaginal Atrophy Therapeutics Revenue in Global Market (2017-2022)
  7.7.5 Bionovo Key News
7.8 QuatRx Pharmaceutical Company
  7.8.1 QuatRx Pharmaceutical Company Corporate Summary
  7.8.2 QuatRx Pharmaceutical Company Business Overview
  7.8.3 QuatRx Pharmaceutical Company Postmenopausal Vaginal Atrophy Therapeutics Major Product Offerings
  7.8.4 QuatRx Pharmaceutical Company Postmenopausal Vaginal Atrophy Therapeutics Revenue in Global Market (2017-2022)
  7.8.5 QuatRx Pharmaceutical Company Key News
7.9 Bayer AG
  7.9.1 Bayer AG Corporate Summary
  7.9.2 Bayer AG Business Overview
  7.9.3 Bayer AG Postmenopausal Vaginal Atrophy Therapeutics Major Product Offerings
  7.9.4 Bayer AG Postmenopausal Vaginal Atrophy Therapeutics Revenue in Global Market (2017-2022)
  7.9.5 Bayer AG Key News
7.10 TherapeuticsMD
  7.10.1 TherapeuticsMD Corporate Summary
  7.10.2 TherapeuticsMD Business Overview
  7.10.3 TherapeuticsMD Postmenopausal Vaginal Atrophy Therapeutics Major Product Offerings
  7.10.4 TherapeuticsMD Postmenopausal Vaginal Atrophy Therapeutics Revenue in Global Market (2017-2022)
  7.10.5 TherapeuticsMD Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Postmenopausal Vaginal Atrophy Therapeutics Market Opportunities & Trends in Global Market
Table 2. Postmenopausal Vaginal Atrophy Therapeutics Market Drivers in Global Market
Table 3. Postmenopausal Vaginal Atrophy Therapeutics Market Restraints in Global Market
Table 4. Key Players of Postmenopausal Vaginal Atrophy Therapeutics in Global Market
Table 5. Top Postmenopausal Vaginal Atrophy Therapeutics Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Postmenopausal Vaginal Atrophy Therapeutics Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Postmenopausal Vaginal Atrophy Therapeutics Revenue Share by Companies, 2017-2022
Table 8. Global Companies Postmenopausal Vaginal Atrophy Therapeutics Product Type
Table 9. List of Global Tier 1 Postmenopausal Vaginal Atrophy Therapeutics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Postmenopausal Vaginal Atrophy Therapeutics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Postmenopausal Vaginal Atrophy Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Postmenopausal Vaginal Atrophy Therapeutics Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Postmenopausal Vaginal Atrophy Therapeutics Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Postmenopausal Vaginal Atrophy Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Postmenopausal Vaginal Atrophy Therapeutics Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Postmenopausal Vaginal Atrophy Therapeutics Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Postmenopausal Vaginal Atrophy Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Postmenopausal Vaginal Atrophy Therapeutics Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Postmenopausal Vaginal Atrophy Therapeutics Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Postmenopausal Vaginal Atrophy Therapeutics Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Postmenopausal Vaginal Atrophy Therapeutics Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Postmenopausal Vaginal Atrophy Therapeutics Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Postmenopausal Vaginal Atrophy Therapeutics Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Postmenopausal Vaginal Atrophy Therapeutics Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Postmenopausal Vaginal Atrophy Therapeutics Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Postmenopausal Vaginal Atrophy Therapeutics Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Postmenopausal Vaginal Atrophy Therapeutics Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Postmenopausal Vaginal Atrophy Therapeutics Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Postmenopausal Vaginal Atrophy Therapeutics Revenue, (US$, Mn), 2023-2028
Table 30. Endoceutics Corporate Summary
Table 31. Endoceutics Postmenopausal Vaginal Atrophy Therapeutics Product Offerings
Table 32. Endoceutics Postmenopausal Vaginal Atrophy Therapeutics Revenue (US$, Mn), (2017-2022)
Table 33. Accord Healthcare Corporate Summary
Table 34. Accord Healthcare Postmenopausal Vaginal Atrophy Therapeutics Product Offerings
Table 35. Accord Healthcare Postmenopausal Vaginal Atrophy Therapeutics Revenue (US$, Mn), (2017-2022)
Table 36. Pfizer Corporate Summary
Table 37. Pfizer Postmenopausal Vaginal Atrophy Therapeutics Product Offerings
Table 38. Pfizer Postmenopausal Vaginal Atrophy Therapeutics Revenue (US$, Mn), (2017-2022)
Table 39. Novo Nordisk Corporate Summary
Table 40. Novo Nordisk Postmenopausal Vaginal Atrophy Therapeutics Product Offerings
Table 41. Novo Nordisk Postmenopausal Vaginal Atrophy Therapeutics Revenue (US$, Mn), (2017-2022)
Table 42. Teva Pharmaceuticals Corporate Summary
Table 43. Teva Pharmaceuticals Postmenopausal Vaginal Atrophy Therapeutics Product Offerings
Table 44. Teva Pharmaceuticals Postmenopausal Vaginal Atrophy Therapeutics Revenue (US$, Mn), (2017-2022)
Table 45. Shionogi Corporate Summary
Table 46. Shionogi Postmenopausal Vaginal Atrophy Therapeutics Product Offerings
Table 47. Shionogi Postmenopausal Vaginal Atrophy Therapeutics Revenue (US$, Mn), (2017-2022)
Table 48. Bionovo Corporate Summary
Table 49. Bionovo Postmenopausal Vaginal Atrophy Therapeutics Product Offerings
Table 50. Bionovo Postmenopausal Vaginal Atrophy Therapeutics Revenue (US$, Mn), (2017-2022)
Table 51. QuatRx Pharmaceutical Company Corporate Summary
Table 52. QuatRx Pharmaceutical Company Postmenopausal Vaginal Atrophy Therapeutics Product Offerings
Table 53. QuatRx Pharmaceutical Company Postmenopausal Vaginal Atrophy Therapeutics Revenue (US$, Mn), (2017-2022)
Table 54. Bayer AG Corporate Summary
Table 55. Bayer AG Postmenopausal Vaginal Atrophy Therapeutics Product Offerings
Table 56. Bayer AG Postmenopausal Vaginal Atrophy Therapeutics Revenue (US$, Mn), (2017-2022)
Table 57. TherapeuticsMD Corporate Summary
Table 58. TherapeuticsMD Postmenopausal Vaginal Atrophy Therapeutics Product Offerings
Table 59. TherapeuticsMD Postmenopausal Vaginal Atrophy Therapeutics Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Postmenopausal Vaginal Atrophy Therapeutics Segment by Type in 2021
Figure 2. Postmenopausal Vaginal Atrophy Therapeutics Segment by Application in 2021
Figure 3. Global Postmenopausal Vaginal Atrophy Therapeutics Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Postmenopausal Vaginal Atrophy Therapeutics Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Postmenopausal Vaginal Atrophy Therapeutics Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Postmenopausal Vaginal Atrophy Therapeutics Revenue in 2021
Figure 8. By Type - Global Postmenopausal Vaginal Atrophy Therapeutics Revenue Market Share, 2017-2028
Figure 9. By Application - Global Postmenopausal Vaginal Atrophy Therapeutics Revenue Market Share, 2017-2028
Figure 10. By Region - Global Postmenopausal Vaginal Atrophy Therapeutics Revenue Market Share, 2017-2028
Figure 11. By Country - North America Postmenopausal Vaginal Atrophy Therapeutics Revenue Market Share, 2017-2028
Figure 12. US Postmenopausal Vaginal Atrophy Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Postmenopausal Vaginal Atrophy Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Postmenopausal Vaginal Atrophy Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Postmenopausal Vaginal Atrophy Therapeutics Revenue Market Share, 2017-2028
Figure 16. Germany Postmenopausal Vaginal Atrophy Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 17. France Postmenopausal Vaginal Atrophy Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Postmenopausal Vaginal Atrophy Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Postmenopausal Vaginal Atrophy Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Postmenopausal Vaginal Atrophy Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Postmenopausal Vaginal Atrophy Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Postmenopausal Vaginal Atrophy Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Postmenopausal Vaginal Atrophy Therapeutics Revenue Market Share, 2017-2028
Figure 24. China Postmenopausal Vaginal Atrophy Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Postmenopausal Vaginal Atrophy Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Postmenopausal Vaginal Atrophy Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Postmenopausal Vaginal Atrophy Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 28. India Postmenopausal Vaginal Atrophy Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Postmenopausal Vaginal Atrophy Therapeutics Revenue Market Share, 2017-2028
Figure 30. Brazil Postmenopausal Vaginal Atrophy Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Postmenopausal Vaginal Atrophy Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Postmenopausal Vaginal Atrophy Therapeutics Revenue Market Share, 2017-2028
Figure 33. Turkey Postmenopausal Vaginal Atrophy Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Postmenopausal Vaginal Atrophy Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Postmenopausal Vaginal Atrophy Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Postmenopausal Vaginal Atrophy Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 37. Endoceutics Postmenopausal Vaginal Atrophy Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Accord Healthcare Postmenopausal Vaginal Atrophy Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Pfizer Postmenopausal Vaginal Atrophy Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Novo Nordisk Postmenopausal Vaginal Atrophy Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Teva Pharmaceuticals Postmenopausal Vaginal Atrophy Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Shionogi Postmenopausal Vaginal Atrophy Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Bionovo Postmenopausal Vaginal Atrophy Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. QuatRx Pharmaceutical Company Postmenopausal Vaginal Atrophy Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Bayer AG Postmenopausal Vaginal Atrophy Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. TherapeuticsMD Postmenopausal Vaginal Atrophy Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)